Ajax Health (“Ajax”), a privately held clinical-stage platform company focused on developing medical technologies, announced today the closing of an oversubscribed $120 million Series B round of financing with participation from a strong syndicate of new and existing investors...
Ajax was founded in 2017 by Duke Rohlen, a successful medical technology entrepreneur and executive, in partnership with KKR and Aisling Capital. Ajax’s strategy is focused on de-risked medical technology opportunities. Ajax identifies areas of under-served medical need and matches human and financial capital to advance technologies and build strategic value.
“We are thrilled to welcome into Ajax this exceptional, new investor syndicate. Their confidence in Ajax underscores the opportunity that Ajax sees to accelerate investment and innovation in an undervalued medical technology sector. There is a significant need in the medical device space for capital to be deployed into differentiated technologies that leverage seasoned operational teams and rational business models. The new group of investors in Ajax recognizes this opportunity and, with this investment, catalyzes the opportunity for important therapeutic innovation,” said Mr. Rohlen.
About Ajax Health
Ajax Health was formed in 2017 with a $95 million investment from KKR, Aisling Capital and Duke Rohlen. Ajax’s strategy is focused on investing in and accelerating innovative medical technology opportunities that address significant unmet clinical needs. Ajax clusters its investments around therapeutic verticals, such as electrophysiology, and capitalizes on funding inefficiencies that stem from the scarcity of capital in the medical technology space.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180709005854/en/
Source: Ajax Health
View this news release online at:
http://www.businesswire.com/news/home/20180709005854/en
